AstraZeneca, Chembio Diagnostics to develop point-of-care diagnostic test

Chembio Diagnostics announced that it entered into a partnership with AstraZeneca to develop a new point-of-care (POC) diagnostic test to detect an undisclosed biomarker. John Sperzel, chief executive at Chembio, remarked that "through this collaboration, our goal is to leverage Chembio's patented DPP platform and our joint scientific expertise, to develop and commercialise" the POC test.

Under the 18-month agreement, AstraZeneca will pay Chembio up to $2.9 million, subject to the achievement of certain milestones, to develop a quantitative reader-based POC test using the DPP platform, and to submit the test for FDA 510(k) clearance.

Chembio noted that the companies also recently successfully completed technical feasibility for the biomarker detection. Under the agreement, "the new DPP system, which will include the new DPP assay and DPP micro reader, will build upon the previously-completed technical feasibility and is expected to provide quantitative results in 10 minutes from a 10-microlitre sample of fingertip or venous blood," Chembio added.

According to Chembio, the DPP platform is the same technology used for its DPP HIV 1/2 assay, which is both FDA-approved and CE-marked.

Did you like this article?